“111Ag production”
The development of a new radiopharmaceutical is a long process and it takes several years for its introduction into clinical trials. Considering both the relevance of Ag-111 as a radiopharmaceutical precursor for its nuclear and chemical properties, and the promising results obtained with the previous ISOLPHARM_Ag experiment, a new three-year proposal, ISOLPHARM-EIRA, is presented which aims not only to strengthen the already achieved results. , but also to go further, working towards the first in vitro and in vivo tests with radioactive silver. To allow the radiolabelling tests to be performed, small quantities of Ag-111 will be produced using the Triga Mark II reactor of LENA in Pavia.
